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Background: The second-generation antipsychotics (SGAs) are associ-
ated with metabolic disturbances. Diabetic ketoacidosis (DKA) is a rare, but
potentially fatal sign of acute glucose metabolism dysregulation, which may
be associated with the use of SGAs. This study aims to review published re-
ports of patientswith schizophrenia and antipsychotic drug–associatedDKA,
focusing on the effective management of both conditions.
Methods: Using a predefined search strategy, we searched PubMed and
EMBASE from their inception to July 2016. The search terms were related
to “diabetic ketoacidosis” and “antipsychotic medication.” Case reports,
case series, and reviews of case series written in English language were in-
cluded in the review.
Results: Sixty-five reports were analyzed. In most patients who devel-
oped antipsychotic-associatedDKA, 1 or more suspected antipsychotic med-
ications were discontinued. In 5 cases, a rechallenge test was trialed, and in
only 1 case, it resulted in the elevation of blood glucose. The majority was
subsequently treated with a different SGA in combination with insulin/oral
hypoglycemic agents; although approximately a third of patients had a com-
plete resolution of symptoms or could control diabetes with diet only at the
point of discharge.
Conclusions: Patients taking antipsychotic medications should be regu-
larly screened for insulin resistance and educated about potential complications
of antipsychotic medications. This will allow clinicians to individualize treat-
ment decisions and reduce iatrogenic contribution to morbidity and mortality.
To achieve best treatment outcomes, antipsychotic-induced DKA should be
treated jointly by psychiatry and endocrinology teams.
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584 www.psychopharmacology.com Journal of CliT he second-generation antipsychotics (SGAs) are consideredas the first line treatment for schizophrenia spectrum disor-
ders. In addition to their effectiveness in treating psychotic symp-
toms, most SGAs are associated with significant weight gain and
the development of glucose intolerance, thus causing diabetes
mellitus, metabolic syndrome, and overall increased risk of car-
diovascular morbidity and mortality.1–3
Diabetic ketoacidosis (DKA) is an acute complication of di-
abetes that mainly occurs in patients with type 1 diabetes, but it is
not uncommon in patients with type 2 diabetes. This condition is a
complex disordered metabolic state characterized by hyperglyce-
mia, ketoacidosis, and ketonuria. With prompt treatment, DKA
can be corrected without any complications developing. If left un-
treated, the condition can be life threatening. Diabetic ketoacidosis
was once considered a hallmark feature that would differentiate in-
dividuals with diabetes mellitus type 1 from those with diabetes
mellitus type 2, although reports of DKA occurring in patients with
diabetes mellitus type 2 were described as well.4 Epidemiologic
studies have estimated that DKA-related hospitalizations have in-
creased over the past 2 decades, reaching the rates of 32.4 per
1000 among people younger than 45 years, 3.3 among people
aged 45 to 64 years, and 1.4 among people 65 years or older.5
Interestingly, in schizophrenia, DKA is often the first sign of
antipsychotic (AP) drug–associated diabetes mellitus among pa-
tients. For example, Henderson et al6 showed that the incidence
of diabetes presenting as DKA in this population is more than
10-fold higher than that in the general population. Among those
with preexisting diabetes mellitus, the rate is 30-fold higher.7 Other
risk factors include polypharmacy, olanzapine monotherapy, cloza-
pine monotherapy, male sex, and middle age (45–60 years).8
Antipsychotic-associated DKA has been associated with 13%
mortality rate.9,10
The management of DKA (irrespective of whether it is part
of diabetes mellitus type 1 or 2) consists of intravenous insulin
therapy with concomitant glucose administration when plasma
glucose levels fall below 300 mg/dL (16.7 mmol/L), sufficient
volume and electrolyte replacement, and careful attention to iden-
tification and management of associated problems, such as acute
pancreatitis and infection.4 Despite all this, no recommendations
exist for management of DKA in psychiatric patients. Given the
long-term nature of psychiatric treatments, as well as high mortal-
ity rates of AP drug–associated DKA, this condition represents a
compelling treatment challenge throughout the course of illness.
This study aims to review published reports of patients with
schizophrenia and AP drug–associated DKA, focusing on the
management of SGA-induced DKA.METHODS
Using a predefined search strategy, we searched PubMed and
EMBASE from their inception to July 2016. The search terms included
“diabetic ketoacidosis,” “antipsychotics,” “atypical antipsychotics,” “firstnical Psychopharmacology • Volume 37, Number 5, October 2017
TABLE 1. Treatment Strategies Including AP Medication After AP-Associated DKA
AP Medication
Initial SGA (n = 58) Switch After SGA-Induced DKA and Outcome
Olanzapine (O) (n = 26) 7 continued (in 5 cases with insulin, in 1 insulin + OHT, in 1 without OHT)
19 discontinued:
• 1 rechallenge, then again discontinued—switched to Q, then discontinued
and switched to Cl (with insulin)
• 11 switched to 5 R (3 cases with insulin, 2 cases with insulin + OHT)
∎ 2 Z (no HT)
∎ 1 Q (with insulin)
∎ 1 A (with OHT)
∎ 2 FGA (1 with insulin, 1 without OHT)
• 2 with no APs (1 with insulin, 1 with OHT)
• 5 N/R on AP therapy (without HT)
Clozapine (Cl) (n = 17) 2 continued (with OHT)—1 after rechallenge
15 discontinued:
• 2 rechallenge then again discontinued—1 switched to FGA (with OHT)
and 1 with no APs and HT
• 9 switched to 5 FGA (2 cases with insulin, 1 with insulin + OHT,
2 cases without HT)
∎ 1 A then discontinued and switched to FGA (N/R HT)
∎ 2 R one then discontinued and switched to FGA (with OHT)
∎ 1 O (with OHT)
• 4 N/R on AP therapy (2 with insulin, 2 without OHT)
Risperidone (R) (n = 6) 1 continued (with insulin)
5 discontinued:
• 4 switched to 2 FGA (with insulin)
∎ 1 Q (with insulin)
∎ 1 Z (without HT)
• 1 N/R on AP therapy/HT
Aripiprazole (A) (n = 6) 1 continued (with insulin)
5 discontinued:
• 1 switched to FGA (with insulin)
• 1 without APs (with insulin)
• 3 N/R on AP therapy (1 case with insulin; 1 with insulin + OHT;
1 N/R on HT)
Quetiapine (Q) (n = 3) 3 discontinued:
• 2 switched to 1 FGA (with OHT)
∎ 1 FGA + R (with OHT)
• 1 N/R on later AP therapy (without HT)
HT indicates hypoglycemic therapy; N/R, no record; FGA, first-generation AP.
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zapine,” “olanzapine,” “risperidone,” “quetiapine,” “ziprasidone,”
“aripiprazole,” “paliperidone,” “amisulpride,” and “haloperidol.” We
also conducted hand searches of key journals and publications of ex-
perts in the field for potentially relevant articles. Articles reporting
clinical cases of DKA associated with the use of AP agents were in-
cluded. Only articles published in English language were included.
All potential studies were exported into reference manage-
ment software. Next, duplicates were removed, and we conducted
the initial screening of titles and abstracts for inclusion against the
eligibility criteria. The full texts of articles meeting the criteria
were obtained and reviewed. Datawere extracted on patients char-
acteristics (sociodemographic and clinical status) and psychiatric
pharmacotherapy associated with DKA before and after the occur-
rence of DKA.
Using these key words, we selected 168 titles. After reading
the article titles, we selected 140 abstracts in English-language ar-
ticles from the period 1994 to 2015. Of these abstracts, we se-
lected 83 case reports and reviews of case series and included
them into the review. A total of 18 cases were excluded because
of lack of provided information: in 11 cases, there was no record
of AP therapy after DKA, and in 7 cases, patients were deceased.© 2017 Wolters Kluwer Health, Inc. All rights reserved.After applying the inclusion and exclusion criteria, 65 reports
were included in this review. The final list included 44 case reports
and 6 case series (Table 1, Fig. 1).
RESULTS
Sociodemographic and clinical characteristics of the patients
are summarized in the Supplemental Digital Content 1, Supple-
mentary Table (http://links.lww.com/JCP/A474).10–59
Antipsychotic Medication
Results of treatment options after AP drug–associated DKA are
summarized in Figure 1. In the majority of reported cases (n = 58),
DKAwas associated with SGA monotherapy: olanzapine (n = 26),
clozapine (n = 17), risperidone (n = 6), aripiprazole (n = 6), and
quetiapine (n = 3). In most cases, the suspected SGA was with-
drawn from treatment after detecting DKA. Subsequently, patients
were put on different AP medications, as shown in Table 2.
In 5 cases, a rechallenge test was trialed. In 2 cases, clozapine
was restarted 24 days and 2 months after the DKA, respectively.
However, in both cases, clozapinewas again discontinued because
of elevation of serum glucose levels. In 1 case, clozapine waswww.psychopharmacology.com 585
FIGURE 1. CONSORT (Consolidated Standards of Reporting Trials) diagram to report results of treatment options after AP-associated DKA.
FGA indicates first-generation AP; R, risperidone; Z, ziprasidone; Q, quetiapine; A, aripiprazole; O, olanzapine; Cl, clozapine.
Vuk et al Journal of Clinical Psychopharmacology • Volume 37, Number 5, October 2017restarted and continued because of treatment resistance to other
APs. Every subsequent discontinuation of clozapine due to the pa-
tient's noncompliance resulted in glucose level normalization,
followed by the elevation of glucose levels after clozapine reintro-
duction. In 1 case, olanzapine was restarted after 1 month and
discontinued after 3 days because of elevation of serum glucose
levels. Blood glucose levels stabilized with oral hypoglycemic
therapy (OHT). The patient was prescribed with clozapine, which
again led to elevated glucose serum levels, regardless of the in-
creased dose of OHT. One successful rechallenge was described in
the patient treated with risperidonewhere DKA developed shortly af-
ter perospirone hydrochloride (a novel serotonin-dopamine antago-
nist) was added to risperidone. Risperidone was restarted in
monotherapy 2 weeks after the DKAwas detected, while insulin
therapy was gradually replaced with diet.
In 7 cases, DKAwas associated with polypharmacy, and au-
thors reported the discontinuation of 1 or even both suspected
agent (Fig. 1).
Antidiabetic Treatment
After the acute treatment of DKA, 19 patients completely re-
covered, and/or 10 patients were able to control diabetes mellitus586 www.psychopharmacology.comwith diet only. Among the patients who were discharged without
antidiabetic treatment, in 1 case, hyperglycemiawas reported after
6 months, but the circumstances in which this occurred were not
reported. However, the majority of patients needed antidiabetic
treatment with insulin (n = 30), oral hypoglycemic agent (n = 9),
or both4 at the time of hospital discharge regardless of the change
in AP treatment. Among those who were discharged from the
hospital with antidiabetic medication, the majority still needed
antidiabetic treatment (n = 24) in the follow-up period; 5 patients
had a complete resolution of diabetes mellitus, and the rest were lost
in the follow-up (n = 14).
The hypoglycemic therapy after DKA is presented in
Figure 2. In cases where APs were discontinued after DKA, the
majority of patients were discharged without any antidiabetic
medication. On the contrary, in cases where the same DKA-
inducing AP was continued, most patients required insulin antidi-
abetic therapy at the time of discharge.
DISCUSSION
This literature review reveals that clinicians tend to use sev-
eral strategies when treating patients with AP-associated DKA:
(1) acute management includes discontinuation of the suspected© 2017 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Recommended Treatment Strategies for Patients at Risk of AP-Associated DKA
Psychiatrist: Preventive Measures
• Obtain personal and family history of diabetes.
• Monitor physical and laboratory measurements: BMI (baseline/monthly), abdominal girth (baseline/annually), blood pressure (baseline/
3 mo/annually), fasting lipid profile (baseline/3 mo/annually).
• Monitor fasting plasma glucose (baseline/1 wk/3 mo/annually).
• Evaluate glycemia immediately if the patient experiences polyuria, weight loss, and thirst.
• Evaluate glycemia with 2-h oral glucose tolerance test with 75 g glucose in patients who (1) are overweight or obese, (2) have positive
family history of diabetes, (3) personal history of gestational DM, (4) laboratory values of glucose intolerance in medical history.
• For patients with prediabetes, which according to American Diabetes Association criteria denotes (1) patients with impaired fasting
glucose (fasting glucose ≥5.6 mmol/L) and/or (2) postprandial glucose intolerance (2-h plasma glucose ≥7.8 mmol/L) and/or (3) HBA1c
≥5.7% (39 mmol/mol), monitoring should include glycated hemoglobin.
• Educate the patients and caregivers on symptoms and signs of diabetes.
Diabetologist: Acute Treatment of Patients With AP-Associated DKA
• Exclude the suspected agent in acute DKA.
• Follow the treatment protocol as in DM type 1: obtain metabolic stabilization with multiple daily injections scheme; ICA, IAA, and GAD
antibodies should be obtained.
• Suspect AP-induced DKA/DM type 2.
• If antibodies are negative, discontinue the suspected SGA and gradually taper insulin (first the short-acting prandial one, then long-acting one);
introduce metformin to reduce insulin resistance.
Multidisciplinary Approach: Post–Acute Treatment of Patients With AP-Associated DKA
• After discharge, these patients should be closely monitored by a diabetologist, to obtain slow reduction of insulin dose and possibly omission
of insulin based on glycemic values (first reduce prandial and then basal insulin).
• Introduce metformin after the probable insulin discontinuation has been successfully achieved if there are no contraindications for metformin.
Themaximal dose of 2 g per day bid divided should be introduced until HbA1c reaches less than 6%, then reduce the daily dose of metformin by
half, and monitor HbA1c in the next 3 to 6 mo. If HbA1c is lower than 6%, metformin should be excluded from therapy.
• Revision of AP therapy should include switching to another SGAwith lower propensity to DKA, unless it is already proven that the change in
the basic AP will lead to significant deterioration of the patient's psychiatric status.
DM indicates diabetes mellitus; BMI, body mass index; ICA, islet cell antibodies; IAA, insulin autoantibodies; GAD, glutamic acid decarboxylase
antibodies.
FIGURE 2. Hypoglycemic therapies after AP-induced DKA. HT
indicates hypoglycemic therapy; ins, insulin; N/R, no record; AP,
AP therapy; FGA, first-generation AP.
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and lifestyle changes (eg, diabetic diet); (2) post-DKA manage-
ment includes switching to a different AP medication with lower
propensity or reintroduction of the same AP medication. Most pa-
tients require continuous antidiabetic treatment. In several cases,
both AP and antidiabetic treatment were discontinued.
The reintroduction of the same AP medication seems the
least optimal because it is associated with a significant risk of re-
lapse of diabetes mellitus or DKA. In the few cases where rechal-
lenge was tried with the same therapeutic agent or the one from
the similar pharmacological group (olanzapine, clozapine), glu-
cose dysregulation was observed despite the use of insulin/or oral
antidiabetic agent. Furthermore, in most cases, the maintenance of
the same AP therapy required insulin therapy in multiple daily in-
jection therapy. Apart from being very demanding on patients, there
are numerous risks associated with such therapy (eg, hypoglycemia,
ketoacidosis, chronic complications, etc), especially given the low
compliance of patientswithmajor psychiatric disorders.60 Therefore,
the decision to reintroduce the same AP together with insulin or oral
antidiabetic should require a careful risk assessment taking into ac-
count the patient's psychiatric status, possibility to achieve remission
with another AP, risk of new DKA, and the possibility to maintain
normoglycemia. Given the periodic nature of schizophrenia and
bipolar disorder, the option to discontinue both AP and antidia-
betic treatment is not suggested either, as the risk of relapse of
psychiatric symptoms is significant.61
Our results show that emergency treatment with insulin and
fluid resuscitation led to complete recovery of AP-induced DKA
in most cases.62–66 However, this was found only when the
suspected drugwas discontinued. According to recently published
reports, DKA does not seem to be a time-limited medical event.
According to Guenette et al,10 after acute treatment of DKA,© 2017 Wolters Kluwer Health, Inc. All rights reserved.36% of patients had complete resolution of symptoms and re-
quired no treatment, 14% controlled diabetes mellitus with diet,
and 50% relied on insulin, oral hypoglycemic agents, or both.8
Similarly, we found that most reported patients needed continua-
tion of antidiabetic therapy at the time of discharge. This might re-
flect a certain degree ofβ-cell failure, which possibly persists after
the AP-associated DKA, although to the best of our knowledge no
data were published on this topic.
Our findings indicate that patients with glucose intolerance
needing AP treatment require interdisciplinary management pro-
vided by psychiatry and diabetology teams. In line with thewww.psychopharmacology.com 587
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tion consensus conference (2016)67 recommendations for meta-
bolic monitoring of patients receiving atypical APs, psychiatrists
should perform the following: obtain data on personal and family
history of diabetesmellitus, screen at baseline and regularlymonitor
physical and laboratory indicators including waist circumference
and glucose and lipids in blood, regularly assess adverse effects,
and educate patients and their caregivers aboutAP-associated adverse
effects. Diabetologists should diagnose and treat acute DKA fol-
lowing the treatment protocol (intravenous and later subcutaneous
application of insulin) and make recommendations based on the
type of diabetes. After DKA is diagnosed, the preferred treatment
options include (1) exclusion of suspected agent in acute DKA;
(2) application of the standard therapy for DKA; (2) given the mor-
bidity and mortality associated with diabetes mellitus, as well as the
need for long-term treatment, switching to another SGAwith lower
propensity toDKA, unless it is already proven that the change in the
basic AP will lead to significant deterioration of the patient's psy-
chiatric status; (3) slow reduction of insulin dose and possibly omis-
sion of insulin based on glycemic values (first reduce prandial and
then basal insulin); (4) if there are no contraindications for metfor-
min, the maximal dose of 2 g per day bid divided should be intro-
duced until glycated hemoglobin (HbA1c) reaches less than 6%.
At that point, we recommend reducing the daily dose of metformin
by half andmonitoring HbA1c in the next 3 to 6months. If HbA1c is
lower than 6%, metformin should be excluded from therapy. Rec-
ommendations are summarized in Table 2.
CONCLUSIONS
The majority of the patients who developed AP-associated
DKAwere subsequently treated with a different SGA in combina-
tion with insulin/oral hypoglycemic. The field lacks prospective
studies with longer follow-up of these patients. Therefore, the pos-
sible implications of these treatments over the longer course of ill-
ness remain unclear. Increased awareness of this problem among
clinicians and patients is needed, as well as primary and secondary
preventive actions such as systematic and periodic screening for
insulin resistance and educating patients about potential complica-
tions of AP treatment. Patients with AP-induced DKA should be
treated by psychiatry and diabetology teams and followed up to
ensure somatic and mental health of these patients.
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